June 2010
Pharmaceutical Representative;Jun2010, Vol. 40 Issue 6, p11
The article reports on the approval of Roche Pharmaceuticals and OSI Pharmaceuticals Inc.'s Tarceva (erlotinib), a maintenance treatment for non-small cell lung cancer.


Related Articles

  • Roche/OSI Pharmaceuticals: Tarceva gains unexpected approval.  // PharmaWatch: Monthly Review;Jun2010, Vol. 9 Issue 6, p6 

    In this article the author discusses the approval given by the U.S. Food and Drug Administration (FDA) to F. Hoffman-La Roche Ltd. and OSI Pharmaceuticals Inc.'s Tarceva for maintenance treatment of non-small cell lung cancer (NSCLC). The author mentions that the approval was unexpected...

  • OSI Pharmaceuticals' lung cancer drug obtains FDA priority review status.  // PharmaWatch: Biotechnology;November 2004, Vol. 3 Issue 11, p11 

    Reports that the application of oncology-focused New York biotechnology firm OSI Pharmaceuticals for lung cancer treatment, Terceva (erlotinib HCl), was accepted and reviewed by the U.S. Food and Drug Administration. Development of Terceva with Roche and Genentech; Milestone payments that will...

  • NSCLC: Tarceva to overtake Iressa?  // PharmaWatch: Cancer;June 2004, Vol. 3 Issue 6, p12 

    Comments on the survival benefit demonstrated in a phase III clinical trial of Tarceva for the treatment of advanced non-small cell lung cancer co-developed by OSI Pharmaceuticals, Genentech and Roche. Significant advance in the treatment of the cancer seen in the trial.

  • New data suggests new lung cancer drug, Tarceva, extends patient survival.  // PharmaWatch: Cancer;June 2004, Vol. 3 Issue 6, p14 

    Examines data suggesting that lung cancer drug, Tarceva, extends patient survival, based on clinical studies conducted by OSI Pharmaceuticals, Genentech and Roche. Significant advancement in treating patients with relapsed non-small cell lung cancer.

  • For the Treatment of Mutated EGFR Non-Small-Cell Lung Cancer, the Majority of Surveyed European Oncologists Indicate That Tarceva Will Threaten the Market Position of Iressa.  // Biomedical Market Newsletter;11/7/2011, Vol. 21, p755 

    The article reports on the findings of the survey conducted by Decision Resources about the first-line treatment for epidermal growth factor receptor (EGFR) mutation-positive nonsmall-cell lung cancer in Europe. According to the surveyed oncologists, Tarceva from Genentech Inc., OSI...

  • OSI Pharmaceuticals/Roche: Tarceva faces competition in Japan.  // PharmaWatch: Cancer;Dec2007, Vol. 6 Issue 12, p14 

    The article announces that the drug Tarceva from OSI Pharmaceuticals and Roche Pharmaceutical has been approved in Japan for the treatment of non-small cell lung cancer. The drug is set to face stiff competition from AstraZeneca PLC Iressa. The approval is based on the positive results from...

  • Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415. Limited, Adis International // Drugs in R&D;2003, Vol. 4 Issue 4, p243 

    Erlotinib [Tarceva[sup â„¢], R 1415, CP 358774, OSI 774, NSC 718781] is a small molecular, once-a-day, orally active inhibitor of the epidermal growth factor receptor tyrosine kinase. It is one of a class of anticancer drugs that target the underlying molecular mechanism involving oncogenes...

  • OSI Might Not Need Partner: Roche to Play White knight Roche to Play White Knight. Morrison, Trista // BioWorld Insight;3/22/2010, Vol. 18 Issue 12, p3 

    The article reports on the status of the proposed takeover of Astella Pharma Inc. by OSI Pharmaceuticals Inc. worth 3.5 billion dollars in the U.S. The move did not realize because OSI's board of directors rejected the hostile proposal, while the firm responded by having its own line up of...

  • Earnings Roundup.  // BioWorld Today;10/23/2009, Vol. 20 Issue 205, p5 

    The article reports on the 111 million U.S. dollars in total revenue posted by OSI Pharmaceuticals Inc. in the third quarter of 2009. This represents an 18% gain from 2008. Tarceva (erlotinib) is credited for the 89 million U.S. dollars earnings while 51 million U.S. dollars came from its...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics